Latest Research And Development News

Complii FinTech Solutions reported a solid 6.6% annual increase in recurring revenue and unveiled the first stage of a major CRM overhaul, signaling a strategic push to enhance its capital raising and compliance platform.

Australian Vanadium Limited has made significant strides in its integrated vanadium project, advancing its feasibility study and securing key environmental approvals while preparing to bid for a major Western Australian battery storage project.

Alliance Nickel reported a $769,000 placement and a $422,000 R&D tax refund while progressing its NiWest Nickel-Cobalt Project, despite renegotiating its Stellantis offtake agreement due to market shifts.

Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Dubber Corporation Limited has signed a significant five-year contract with a major North American communications provider, while trimming costs and targeting operating cashflow breakeven in FY26.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Environmental Clean Technologies Limited has completed the acquisition of Terrajoule, gaining exclusive rights to a cutting-edge soil remediation technology targeting PFAS contamination. The company also bolstered its leadership and funding to accelerate commercialisation.

AnteoTech has raised A$3.5 million through a discounted share placement to accelerate commercialisation of its advanced battery and life sciences technologies globally. The capital injection supports strategic partnerships and sales expansion in key markets including the US and India.

AML3D Limited has reported a remarkable 360% increase in customer receipts for the December 2025 quarter, driven by strong demand from the US defence sector and a robust order book of A$16.5 million for FY26. The company is accelerating its US scale-up strategy while expanding into UK and European defence markets.

Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.